AHZANTIVE 40mg / ml solution for injection in pre-filled syringe medication leaflet

S01LA05 • aflibercept • Sensory organs | Ocular vascular disorder agents | Antineovascularisation agents

Aflibercept is a medication used in the treatment of certain ophthalmological and oncological conditions. In ophthalmology, it is indicated for the treatment of wet age-related macular degeneration, diabetic macular edema, macular edema secondary to retinal vein occlusion, and choroidal neovascularization. In oncology, it is used in combination with other medications to treat certain types of cancer, such as metastatic colorectal cancer.

Aflibercept acts as a vascular endothelial growth factor (VEGF) inhibitor, blocking the formation of abnormal new blood vessels and reducing fluid leakage from blood vessels. In ophthalmology, it is administered via intravitreal injections, while in oncology, it is given through intravenous infusion.

Side effects may include eye irritation, eye pain, increased intraocular pressure, or local inflammation in ophthalmological use. In oncological use, side effects may include high blood pressure, fatigue, diarrhea, or an increased risk of bleeding. Administration should be performed under strict medical supervision, and patients should inform their doctor about any other conditions or ongoing treatments.